Key Takeaways
- An experimental drug called invikafusp alfa (invika) is being studied for advanced solid tumors that have stopped responding to standard immunotherapies.
- Research suggests the therapy selectively activates a small group of tumor-fighting T cells, which may help limit widespread side effects.
- In early clinical testing at optimal dosage levels, the treatment stopped tumor growth in over half of the participants and shrank tumors in a subset of patients.
What the Source Says
Research suggests that an experimental protein drug known as invikafusp alfa (invika) may offer a new approach for managing treatment-resistant cancers. A study led by researchers at the National Institutes of Health (NIH), Mass General Brigham, and Memorial Sloan Kettering evaluated the drug in human clinical trials. While traditional immunotherapies can cause severe side effects by activating immune cells broadly, invika was engineered to target a narrow subset of tumor-infiltrating T cells specifically.
In early trial phases, study participants received treatments every two weeks to test safety and determine the optimal dose. Expected flu-like side effects occurred, but researchers noted these were manageable with medication and supportive care. Among 27 participants treated at the identified optimal dose, disease progression stopped in 16 individuals (59.3%). Additionally, 4 participants (14.8%) experienced a reduction of over 30% in targeted tumor size, including patients with metastatic colorectal cancer and stage 4 non-small cell lung cancer whose tumors had resisted prior therapies.
The drug sponsor, Marengo Therapeutics, was granted Fast Track designation by the U.S. Food and Drug Administration (FDA) to evaluate invika for antigen-rich metastatic colorectal cancer and other solid tumors following previous therapies. Scientists at the Center for Cancer Research within the National Cancer Institute (NCI) emphasized that while early immune activity does not always lead to clinical benefits, these findings encourage continued study of the drug.
Practical Notes
This therapy is experimental and is still being evaluated in active research settings. Exact enrollment deadlines and detailed participant criteria are not specified in the source; please check the official notice for complete trial information.
Always speak with your doctor or qualified healthcare professional regarding any medical concerns, cancer care options, or potential clinical trial participation.
Source: NIH News Releases · Published October 23, 2026 · Photo by Omar Abozeid on Unsplash
This article is for general information only and is not medical advice. Talk to your doctor before making health decisions.